HORMONE RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to keep early breast cancer from returning
Disease control OngoingThis study tests a combination of two targeted drugs (trastuzumab and pertuzumab) plus hormone therapy given after surgery for people with stage I hormone receptor-positive, HER2-positive breast cancer. The goal is to see if this approach helps prevent the cancer from coming back…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat breast cancer
Disease control OngoingThis early-stage study tests a new two-part treatment for people with advanced breast cancer that has stopped responding to standard therapies. Participants receive a single infusion of their own engineered immune cells (CLBR001) followed by cycles of an antibody drug (ABBV-461).…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Promising new combo aims to shrink Hard-to-Treat breast tumors before surgery
Disease control OngoingThis study tests whether adding the targeted drug pyrotinib to standard chemotherapy can better shrink tumors before surgery in people with a specific type of early breast cancer (HR-positive, HER2-low, high-risk). About 160 participants will receive either the drug combo or chem…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated May 19, 2026 11:49 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer in early trial
Disease control OngoingThis study tests whether adding the drug pyrotinib to standard chemotherapy before surgery can improve outcomes for women with stage II or III hormone receptor-positive, HER2-negative breast cancer that also has high levels of the HER4 protein. About 140 participants will receive…
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New drug DS-1062a tested in humans for first time against advanced cancers
Disease control OngoingThis study tests a new drug called DS-1062a in people with advanced solid tumors, including certain lung and breast cancers that have not responded to standard treatments. It is the first time this drug is being used in humans, and the main goals are to check its safety and find …
Matched conditions: HORMONE RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC